Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1995 1
1996 2
1997 1
1999 1
2004 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Thymoma: current medical and surgical management.
Kesler KA, Wright CD, Loehrer PJ Sr. Kesler KA, et al. Semin Neurol. 2004 Mar;24(1):63-73. doi: 10.1055/s-2004-829588. Semin Neurol. 2004. PMID: 15229793 Review.
A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma.
Miller KD, Loehrer PJ, Gonin R, Weber G, Ansari R, Pletcher W, McClean J, Spiridonidis CH, Mortimer J. Miller KD, et al. Invest New Drugs. 1996;14(2):207-12. doi: 10.1007/BF00210792. Invest New Drugs. 1996. PMID: 8913842 Clinical Trial.
Hematologic toxicity was severe with 50% of patients developing hemoglobins less than 8 gm/dl and 70% with granulocyte counts less than 1000 per mm3. One patient achieved a radiographic complete remission and 2 had stable disease. Two-thirds of patients progressed within …
Hematologic toxicity was severe with 50% of patients developing hemoglobins less than 8 gm/dl and 70% with granulocyte counts less than 1000 …
Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
Loehrer PJ Sr, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH. Loehrer PJ Sr, et al. J Clin Oncol. 1994 Mar;12(3):483-8. doi: 10.1200/JCO.1994.12.3.483. J Clin Oncol. 1994. PMID: 7509853 Clinical Trial.
For other patients, M-VACII dosages were methotrexate 40 mg/m2 (days 1, 15, and 22), vinblastine 4 mg/m2 (days 2, 15, and 22), doxorubicin 40 mg/m2 (day 2), and cisplatin 100 mg/m2 (day 2). ...
For other patients, M-VACII dosages were methotrexate 40 mg/m2 (days 1, 15, and 22), vinblastine 4 mg/m2 (days 2, 15, and 22), doxoru …
Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial.
Loehrer PJ Sr, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, Johnson D. Loehrer PJ Sr, et al. J Clin Oncol. 1997 Sep;15(9):3093-9. doi: 10.1200/JCO.1997.15.9.3093. J Clin Oncol. 1997. PMID: 9294472 Clinical Trial.
Among the 23 assessable patients, there were five complete and 11 partial responses to chemotherapy (overall response rate, 69.6%). The median time to treatment failure was 93.2 months (range, 3 to 99.2+ months), and the median survival time was 93 months (range, 1 …
Among the 23 assessable patients, there were five complete and 11 partial responses to chemotherapy (overall response rate, 69.6%). The medi …